After reporting robust results, Resmed reckons it won't be subject to US tariffs while the growth of anti-obesity drugs will be a tailwind.

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital ...

Over time, studies have documented potential problems when people get much more than that. Excess fluoride intake has been associated with streaking or spots on teeth. And studies also have traced ...

Morgan Stanley analyst David Bailey maintained a Hold rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) today and set a price target of A$36.70. The company’s ...

Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Parkite distance runner Grant Fisher crosses the finish line in the Valentine Invitational 5000m ...

Investors looking for exposure to the growing field of respiratory healthcare and sleep apnoea treatment may find themselves comparing two ASX-listed giants: Fisher & Paykel Healthcare Corporation ...

Fisher & Paykel Healthcare has announced new tariffs imposed by the United States on products manufactured outside the US, including a 10% tariff on products made in New Zealand. The company said it ...

Becton Dickinson, Thermo Fisher Scientific, Danaher, Waters Corp, Qiagen and Revvity did not immediately respond to a Reuters request for comment. (Reporting by Surbhi Misra and Shubham Kalia in ...

Those poor ratings from voters may signal long-term problems for the party if they persist through the 2028 presidential campaign. But the negative reviews probably won’t have nearly as much ...